Answers are grounded in this paper and cite their sources.
In the present paper we report the synthesis and structural IR and 1 H and 13 C NMR characterization of four platinum(II) and palladium(II) cyclometalated complexes of the formula [Pd(4-ClC 6 H 4 N C(COC 6 H 5 )C 6 H 4 )X] 2, where X = OAc ( 2 ) or Cl ( 3 ), and [Pt(4-ClC 6 H 4 N C(COC 6 H 5 )C 6 H 4 )X] 2, where X = Cl ( 4 ) or OAc ( 5 ). The acetate-bridged compounds 2 and 5 have an open-book structure. The chloro-bridged compounds 3 and 4 have an unfolded structure. Complex 2 crystallizes in the centrosymmetric triclinic space group P 1̄, with Z = 2. Unit cell parameters are as follows: a = 11.765(3) Å, b = 12.862(4) Å, c = 15.022(5) Å, α = 84.08(2)°, β = 78.56(2)°, γ = 83.13(2)°. All these compounds were screened against MDA-MB 468 (breast carcinoma) and HL-60 (leukemic) tumor cells. The low IC 50 values of compound 5 (1.05 μM) and of compound 4 (1.58 μM) against MDA-MB 468 and of 0.82 μM ( 5 ) and 1.37 μM ( 4 ) against HL-60 relative to cis -DDP (2.67 and 2.07 μM, respectively) and other cyclometalated compounds suggest that the synthesized compounds may be regarded as having potential antitumor properties. The data suggest that the antiproliferative activity of compound 5 may correlate with its covalent binding to DNA and the induction of important modifications on the helix.
No takes yet. Share an insight, caveat, or question.
Navarro‐Ranninger et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: